

## A novel case of homozygous IFNAR1 deficiency with haemophagocytic lymphohistiocytosis

Florian Gothe<sup>ϕ</sup> MD<sup>1,2</sup>

Catherine F. Hatton<sup>ϕ</sup> MSc<sup>1</sup>

Linh Truong<sup>ϕ</sup> BSc<sup>1</sup>

Zofia Klimova MD<sup>3</sup>

Veronika Kanderova<sup>4</sup>

Martina Fejtkova<sup>4</sup>

Angela Grainger<sup>1</sup>

Venetia Bigley PhD<sup>1,5</sup>

Joanna Perthen PhD<sup>6</sup>

Dipayan Mitra MD<sup>6</sup>

Ales Janda MD PhD<sup>7</sup>

Eva Fronkova MD<sup>4</sup>

Dusana Moravcikova MD<sup>3</sup>

Sophie Hambleton DPhil<sup>1,8</sup>

Christopher J.A. Duncan DPhil<sup>\*1,9</sup>

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, UK.
2. Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
3. Banská Bystrica Children's University Hospital, Banská Bystrica, Slovakia.
4. Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
5. Northern Centre for Bone Marrow Transplant, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, UK.
6. Department of Neuroradiology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, UK.
7. Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Germany.
8. Children's Immunology Service, Great North Children's Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, UK.
9. Infection and Tropical Medicine, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, UK.

<sup>†</sup> These authors contributed equally

\*Corresponding author:

Dr. Christopher J. A. Duncan DPhil

Translational and Clinical Research Institute

Immunity & Inflammation Theme

Faculty of Medical Sciences

Room M3.119

3rd Floor, Leech Building

Newcastle University Medical School

Newcastle upon Tyne

NE2 4HH

Tel: +44(0)191 2087362

Fax: +44(0)191 2085455

[christopher.duncan@ncl.ac.uk](mailto:christopher.duncan@ncl.ac.uk)

Accepted Manuscript

**Abstract:** We present a case of complete deficiency of the Interferon alpha/beta receptor alpha chain (IFNAR1) in a child with fatal systemic hyperinflammation, apparently provoked by live-attenuated viral vaccination. Such pathologic hyperinflammation, fulfilling criteria for haemophagocytic lymphohistiocytosis, is an emerging phenotype accompanying inborn errors of type I interferon immunity.

**Key words:** IFNAR1, type I interferon, HLH, inborn error of immunity

Accepted Manuscript

## Main text:

Type I interferons (including IFN $\beta$  and 13 IFN $\alpha$  subtypes), signal via a single ubiquitously-expressed receptor composed of low and high affinity subunits, IFNAR1 and IFNAR2. Type I IFNs appear critical to mammalian antiviral immunity, based on extensive studies of *Ifnar1*-deficient mice, but their precise role in humans was hitherto uncertain<sup>1</sup>. Our discovery of complete human IFNAR2 deficiency in a child with fatal viral disease secondary to live-attenuated measles mumps and rubella (MMR) vaccination implied an essential antiviral function<sup>2</sup>. It was nevertheless striking that the proband displayed no overt viral susceptibility prior to MMR exposure. This phenotype of disease provoked by challenge with systemic live-attenuated viral vaccination was seen in two patients with IFNAR1 deficiency, both similarly healthy until vaccination<sup>3</sup>. However, the recent identification of *IFNAR1* variants in two patients with severe SARS-CoV-2 highlights the additional importance of type I IFNs in immunity to naturally-acquired viruses<sup>4</sup>.

In this study, we investigated a previously well 15 month-old boy who developed severe illness following MMR vaccination, comprising progressive and ultimately fatal hyperinflammation meeting diagnostic criteria for haemophagocytic lymphohistiocytosis (HLH, see case summary, Fig. 1A, Table E1). Analysis of serum (Table E2) and cerebrospinal fluid (Table E3) did not yield evidence of vaccine-strain viral replication, nor was an alternative infectious aetiology identified, other than low-level Epstein Barr virus (EBV) reactivation. Detailed immune phenotyping showed monocytosis and T cell lymphocytosis, with low numbers of B cells and cDC1 (Fig. E1, Table E4). Despite aggressive antiviral, immunomodulatory therapy and IVIG, he developed encephalopathy with abnormal neuroimaging and succumbed suddenly approximately 6 months after presentation (Fig. E2, E3, E4). Rapid diagnostic whole exome sequencing revealed a novel homozygous nonsense variant (c.922C>T) in *IFNAR1*, introducing a premature stop codon in the third extracellular domain of IFNAR1 protein (p.Gln308Ter, Fig. 1B). This variant was absent from the GnomAD database and predicted to be deleterious by *in silico* tools (Table E5). No protein product was detected when probing primary dermal fibroblast lysates with N-terminal (Fig. 1C) or C-terminal IFNAR1 antibody (Fig. E5), indicative of complete IFNAR1 deficiency. Scrutiny of a comprehensive panel of genes

linked to inborn errors of immunity within the patient's exome data revealed no additional candidate disease-causing variants.

Upon ligand binding, the ternary complex of IFNAR1-IFN-IFNAR2 initiates an intracellular signalling cascade in which reciprocal transphosphorylation of the receptor-associated kinases JAK1 and TYK2 is followed by phosphorylation of the signal transducers and activators of transcription, STAT1 and STAT2. The majority of the transcriptional response to IFN $\alpha\beta$  is attributable to the heterotrimer formed of phosphorylated STATs 1 and 2 together with IRF9. This complex, known as Interferon Stimulated Gene Factor 3 (ISGF3), translocates to the nucleus where it interacts with interferon-sensitive response elements (ISREs) to activate the transcription of a large number of interferon-stimulated genes (ISGs). A fraction of the phospho-STAT1 instead homodimerizes to form the IFN $\gamma$  activation factor (GAF), agonising a distinct but overlapping set of genes bearing IFN $\gamma$  activation sites (GAS), more typically associated with type II IFN (IFN $\gamma$ ) signalling. The predicted effect of IFNAR1 deficiency is to prevent signalling and downstream functional responses to IFN $\alpha\beta$ , but leave intact responses to IFN $\gamma$ .

Consistent with this prediction, phosphorylation of JAK1 and its downstream targets STAT1 and STAT2 was undetectable in IFNAR1-deficient patient fibroblasts exposed to IFN $\alpha$ 2b for 30 minutes, as revealed by immunoblotting of whole cell lysates, whereas phosphorylation of JAK1 and STAT1 upon exposure to IFN $\gamma$  was preserved (Fig. 1D). The same pattern was observed by analysis of STAT1 phosphorylation in patient lymphocytes and monocytes by phospho-flow cytometry (Fig. E6). Accordingly, immunoblotting revealed failure to induce ISG protein products in IFNAR1-deficient patient fibroblasts exposed overnight to IFN $\alpha$ 2b despite intact responses to IFN $\gamma$  (Fig. 1E). To address the functional impact, we challenged cells with the picornavirus encephalomyocarditis virus (EMCV). In this experiment, fibroblasts were pre-treated with IFN $\alpha$ 2b or IFN $\gamma$  overnight prior to infection, at a dose that was previously determined to prevent cytopathic effect (CPE) in control cells, then examined at 24 hours post infection. IFNAR1-deficient cells were susceptible to CPE despite

IFN $\alpha$ 2b exposure, but were rescued by IFN $\gamma$  treatment, confirming a specific defect of IFN $\alpha\beta$ -mediated antiviral immunity (Fig. 1F).

To extend and confirm these findings, we infected cells with the flavivirus Zika virus (ZIKV) at different multiplicities of infection, examining expression of viral envelope protein and ISGs by immunoblot at 48 hours post infection (Fig. 1G). In patient cells, we saw excessive viral protein expression (Fig. E7), accompanied by the failure to induce expression of ISG15, RSAD2 and MX1, reflecting a defect of IFNAR-mediated antiviral resistance and correlated with susceptibility to viral cytotoxicity (Fig. 1H). Treatment of patient cells with exogenous IFN $\gamma$ , but not IFN $\alpha$ 2b, prevented ZIKV infection (Fig. 1I) and CPE (Fig. 1J).

To prove definitively that the loss of IFNAR1 was responsible, we complemented patient fibroblast cells with full-length human *IFNAR1* delivered by lentiviral transduction. Lentiviral transduction of *IFNAR1* in patient fibroblasts, but not empty vector, restored induction of ISGs (Fig. 1K) and formation of an antiviral state in response to IFN $\alpha$ 2b (Fig. 1L), thereby confirming the genotype-phenotype association.

We report a new case of complete IFNAR1 deficiency, complementing a recent report of homozygous IFNAR1 deficiency in two unrelated children<sup>3</sup>. In all three of these cases, and similar to IFNAR2 deficient patients<sup>2</sup>, viral susceptibility became apparent only following inoculation with live-attenuated viral vaccines. At first sight, this contrasts with the broader susceptibility of STAT2- or IRF9-deficient patients<sup>6-8</sup> to viruses naturally encountered at mucosal surfaces, which might be explicable in terms of functional redundancy between type I and type III IFNs at the mucosa<sup>1</sup>. However, the recent discovery of two further cases of IFNAR1 deficiency among persons with severe COVID-19 implies that, for SARS-CoV-2 at least, type I IFNs can play a defining role in the host response to natural pathogens<sup>4</sup>. This conclusion is further supported by the detection of neutralizing antibodies against type I but not type III IFNs in 10% of severe COVID-19 cases<sup>4</sup>, as well as a genome-wide association signal with *IFNAR2* in an independent cohort<sup>9</sup>.

Our case expands the phenotypic spectrum of IFNAR1 deficiency to include HLH-like hyperinflammation, previously noted in IFNAR2 deficiency and increasingly recognised in other

defects of IFN $\alpha\beta$  immunity such as STAT2 or IRF9 defects<sup>8,10</sup>. Defining the pathomechanism of hyperinflammation in this context, particularly its relationship to dysregulated inflammatory signalling and/or viral replication, is an important area for future work. Despite the temporal association with vaccination, our case was notable for the absence of detectable vaccine-strain dissemination. A similar picture has been observed in some STAT1- and STAT2-deficient patients with hyperinflammation<sup>11,12</sup>. Whilst we could not exclude a contribution of low-level EBV reactivation, sterile autoinflammation has emerged as a distinct clinical phenotype in defects of IFN $\alpha\beta$  signalling<sup>8</sup>. This suggests a more complex mechanism involving the loss of IFN $\alpha\beta$  regulation<sup>1</sup>. On the face of it this is paradoxical, since uncontrolled IFN $\alpha\beta$  signalling is itself associated with HLH-like sterile inflammation<sup>13</sup>. Yet IFN $\alpha\beta$  also negatively regulates various cytokine pathways, including IL1 $\beta$ <sup>14</sup> and IL17<sup>15</sup>. Immunomodulatory properties of IFN $\beta$  are exploited in therapy for immune-mediated diseases such as multiple sclerosis. The partial clinical response to corticosteroids and IL1 $\beta$  blockade in our case lends some support to the hypothesis that loss of IFN $\alpha\beta$  signalling contributes to disordered immune network activity. In the context of viral disease, it appears that a correctly calibrated IFN $\alpha\beta$  response is necessary to prevent immunopathology. This is the ‘goldilocks’ principle of immune homeostasis, where both inadequate and excessive activity contributes to disease.

Hyperinflammation is central to the pathogenesis of severe COVID-19, as demonstrated by the clinical effectiveness of corticosteroids. Our novel case of IFNAR1 deficiency reveals a potential role for IFN $\alpha\beta$  in preventing hyperinflammation, not simply through direct control of viral replication<sup>2,3</sup> but possibly also via its immunoregulatory action towards other cytokines. The loss of both aspects of IFN $\alpha\beta$  function might contribute to the susceptibility of patients with *IFNAR1* defects to severe COVID-19<sup>4,9</sup>. Understanding the cellular and molecular links between defective IFN $\alpha\beta$  signalling and pathogenic inflammation will be critical in guiding therapy for severe viral disease.



**Potential conflicts:**

FG received funding from the Deutsche Forschungsgemeinschaft [GO2955/1-1] as well as the Bubble Foundation. CFH is funded by an MRC studentship [MR/N013840/1]. VK, EF and MF are funded by the Ministry of Health of the Czech Republic [NV19-05-00332]. SH and CJAD are funded by the Wellcome Trust [207556/Z/17/Z and 211153/Z/18/Z respectively]. The other authors have no financial relationships to disclose.

Accepted Manuscript

## References

1. Duncan, C. J. A., Randall, R. E. & Hambleton, S. Genetic Lesions of Type I Interferon Signalling in Human Antiviral Immunity. *Trends Genet.* **xx**, 1–13 (2020).
2. Duncan, C. J. A. *et al.* Human IFNAR2 deficiency: Lessons for antiviral immunity. *Sci. Transl. Med.* **7**, (2015).
3. Hernandez, N. *et al.* Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. *J. Exp. Med.* **216**, 2057–2070 (2019).
4. Zhang, Q., Bastard, P. & Liu, Z. Inborn errors of type I IFN immunity with life-threatening COVID-19. *Science (80-. )*. **21**, 1–9 (2020).
5. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434–443 (2020).
6. Hambleton, S. *et al.* STAT2 deficiency and susceptibility to viral illness in humans. *Proc. Natl. Acad. Sci.* **110**, 3053–3058 (2013).
7. Hernandez, N. *et al.* Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency. *J. Exp. Med.* **215**, 2567–2585 (2018).
8. Bravo García-Morato, M. *et al.* Impaired control of multiple viral infections in a family with complete IRF9 deficiency. *J. Allergy Clin. Immunol.* **144**, 309-312.e10 (2019).
9. Pairo-Castineira, E. *et al.* Genetic mechanisms of critical illness in Covid-19. *medRxiv* 2020.09.24.20200048 (2020). doi:10.1101/2020.09.24.20200048
10. Alosaimi, M. F. *et al.* A novel variant in STAT2 presenting with hemophagocytic lymphohistiocytosis. *J. Allergy Clin. Immunol.* **144**, 611-613.e3 (2019).
11. Burns, C. *et al.* A novel presentation of homozygous loss-of-function STAT-1 mutation in an infant with hyperinflammation—A case report and review of the literature. *J. Allergy Clin.*

- Immunol. Pract.* **4**, 777–779 (2016).
12. Shahni, R. *et al.* Signal transducer and activator of transcription 2 deficiency is a novel disorder of mitochondrial fission. *Brain* **138**, 2834–2846 (2015).
  13. Duncan, C. J. A. *et al.* Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2. *Sci. Immunol.* **4**, (2019).
  14. Reboldi, A. *et al.* 25-hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon. *Science* (80-. ). **345**, 679–684 (2014).
  15. Liu, L. *et al.* Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis . *J. Exp. Med.* **208**, 1635–1648 (2011).


Accepted Manuscript

**Figure 1.**

(A) Pedigree. (B) Sanger sequencing confirmation of variant with IFNAR1 protein domains. (C) IFNAR1 deficiency (immunoblot). (D) Signalling by IFN $\alpha$ 2b or IFN $\gamma$  (1000 IU/mL, 30m, immunoblot). (E) ISG induction by IFN $\alpha$ 2b or IFN $\gamma$  (1000 IU/mL, 16h, immunoblot). (F) EMCV cytopathicity protection assay. (G) ZIKV envelope (ENV), ISG15, RSAD2 and MX1 expression (immunoblot) in fibroblasts (H) ZIKV cytopathicity assay. Protection against ZIKV by IFN $\alpha$ 2b or IFN $\gamma$  (MOI 1.0, 1000 IU/mL, 24h) by (I) immunoblot and (J) viability assay. Complementation with *IFNAR1* but not empty vector (*VEC*) restores (K) ISG induction by IFN $\alpha$ 2b (1000 IU/mL, 16h, immunoblot) and (L) IFN $\alpha$ 2b-mediated protection against EMCV. All experiments repeated n=3 times in II:1 and control primary fibroblasts. Mean  $\pm$  SD  
\*\*\*\*P<0.001, Two-way ANOVA with Tukey's post-test. \*nonspecific band.

Accepted Manuscript

Figure 1



Accer